FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996637863> ?p ?o ?g. }

• W2996637863 endingPage "4319" @default.
• W2996637863 startingPage "4305" @default.
• W2996637863 abstract "Currently >50% of high-risk neuroblastoma (NB) patients, despite intensive therapy and initial partial or complete response, develop recurrent NB due to the persistence of minimal residual disease (MRD) that is resistant to conventional antitumor drugs. Indeed, their low therapeutic index prevents drug-dose escalation and protracted administration schedules, as would be required for MRD treatment. Thus, more effective and less toxic therapies are urgently needed for the management of MRD. To address this aim, we evaluated a new combination of fenretinide and lenalidomide, both endowed with antitumor activity and low-toxicity profiles. New nanomicelles were prepared as carriers for this combination to maximize bioavailability and accumulation at the tumor site because of the enhanced permeability and retention (EPR) effect.New nanomicelles containing the fenretinide-lenalidomide combination (FLnMs) were prepared by a one-step method, providing high drug encapsulation and micelle dimensions suitable for tumor accumulation. Their administration to mice bearing human NB xenografts allowed us to evaluate their efficacy in comparison with the nanomicelles containing fenretinide alone (FnMs).Treatment by FLnMs significantly decreased the tumor growth of NB xenografts. FLnMs were more active than FnMs despite comparable fenretinide concentrations in tumors, and lenalidomide alone did not show cytotoxic activity in vitro against NB cells. The tumor mass at the end of treatment with FLnMs was predominantly necrotic, with a decreased Ki-67 proliferation index.FLnMs provided superior antitumor efficacy in NB xenografts compared to FnMs. The enhanced efficacy of the combination was likely due to the antiangiogenic effect of lenalidomide added to the cytotoxic effect of fenretinide. This new nanomicellar combination is characterized by a low-toxicity profile and offers a novel therapeutic option for the treatment of high-risk tumors where the persistence of MRD requires repeated administrations of therapeutic agents over long periods of time to avoid recurrent disease." @default.
• W2996637863 created "2019-12-26" @default.
• W2996637863 creator A5002567610 @default.
• W2996637863 creator A5004950779 @default.
• W2996637863 creator A5031609453 @default.
• W2996637863 creator A5052318072 @default.
• W2996637863 creator A5055602430 @default.
• W2996637863 creator A5056359176 @default.
• W2996637863 creator A5064857316 @default.
• W2996637863 creator A5067171086 @default.
• W2996637863 date "2019-12-01" @default.
• W2996637863 modified "2023-10-02" @default.
• W2996637863 title "<p>A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model</p>" @default.
• W2996637863 cites W1846624086 @default.
• W2996637863 cites W1858109422 @default.
• W2996637863 cites W1881059081 @default.
• W2996637863 cites W1945302280 @default.
• W2996637863 cites W1964370179 @default.
• W2996637863 cites W1966953145 @default.
• W2996637863 cites W1980068016 @default.
• W2996637863 cites W1988327939 @default.
• W2996637863 cites W1989758315 @default.
• W2996637863 cites W1994010493 @default.
• W2996637863 cites W1995986211 @default.
• W2996637863 cites W2024817554 @default.
• W2996637863 cites W2041956759 @default.
• W2996637863 cites W2051918616 @default.
• W2996637863 cites W2057666195 @default.
• W2996637863 cites W2067336239 @default.
• W2996637863 cites W2067659186 @default.
• W2996637863 cites W2073260892 @default.
• W2996637863 cites W2085069569 @default.
• W2996637863 cites W2089070253 @default.
• W2996637863 cites W2098860085 @default.
• W2996637863 cites W2099630170 @default.
• W2996637863 cites W2106568960 @default.
• W2996637863 cites W2109463262 @default.
• W2996637863 cites W2128352319 @default.
• W2996637863 cites W2139201146 @default.
• W2996637863 cites W2143217083 @default.
• W2996637863 cites W2151496733 @default.
• W2996637863 cites W2158847914 @default.
• W2996637863 cites W2158904485 @default.
• W2996637863 cites W2171194005 @default.
• W2996637863 cites W2338919347 @default.
• W2996637863 cites W2412797649 @default.
• W2996637863 cites W2414365196 @default.
• W2996637863 cites W2460174227 @default.
• W2996637863 cites W2532153267 @default.
• W2996637863 cites W2554694448 @default.
• W2996637863 cites W2566411080 @default.
• W2996637863 cites W2605660450 @default.
• W2996637863 cites W2605715045 @default.
• W2996637863 cites W2734386926 @default.
• W2996637863 cites W2792870535 @default.
• W2996637863 cites W2884616676 @default.
• W2996637863 cites W2948260295 @default.
• W2996637863 cites W2963581868 @default.
• W2996637863 cites W2969928291 @default.
• W2996637863 cites W3011556 @default.
• W2996637863 doi "https://doi.org/10.2147/dddt.s221909" @default.
• W2996637863 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6930389" @default.
• W2996637863 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31908416" @default.
• W2996637863 hasPublicationYear "2019" @default.
• W2996637863 type Work @default.
• W2996637863 sameAs 2996637863 @default.
• W2996637863 citedByCount "11" @default.
• W2996637863 countsByYear W29966378632020 @default.
• W2996637863 countsByYear W29966378632021 @default.
• W2996637863 countsByYear W29966378632022 @default.
• W2996637863 countsByYear W29966378632023 @default.
• W2996637863 crossrefType "journal-article" @default.
• W2996637863 hasAuthorship W2996637863A5002567610 @default.
• W2996637863 hasAuthorship W2996637863A5004950779 @default.
• W2996637863 hasAuthorship W2996637863A5031609453 @default.
• W2996637863 hasAuthorship W2996637863A5052318072 @default.
• W2996637863 hasAuthorship W2996637863A5055602430 @default.
• W2996637863 hasAuthorship W2996637863A5056359176 @default.
• W2996637863 hasAuthorship W2996637863A5064857316 @default.
• W2996637863 hasAuthorship W2996637863A5067171086 @default.
• W2996637863 hasBestOaLocation W29966378631 @default.
• W2996637863 hasConcept C104317684 @default.
• W2996637863 hasConcept C126322002 @default.
• W2996637863 hasConcept C185592680 @default.
• W2996637863 hasConcept C19831878 @default.
• W2996637863 hasConcept C2775954498 @default.
• W2996637863 hasConcept C2776063141 @default.
• W2996637863 hasConcept C2776364478 @default.
• W2996637863 hasConcept C2776715637 @default.
• W2996637863 hasConcept C2776999253 @default.
• W2996637863 hasConcept C2780035454 @default.
• W2996637863 hasConcept C2780533455 @default.
• W2996637863 hasConcept C2781121885 @default.
• W2996637863 hasConcept C29730261 @default.
• W2996637863 hasConcept C502942594 @default.
• W2996637863 hasConcept C54355233 @default.
• W2996637863 hasConcept C55493867 @default.
• W2996637863 hasConcept C71924100 @default.

• next